Treatment failure due to the potential under-dosing of dihydroartemisinin-piperaquine in a patient with Plasmodium falciparum uncomplicated malaria

Infectious Diseases and Tropical Medicine 2019; 5: e525
DOI: 10.32113/idtm_20195_525

  Topic: Parasitic diseases     Category:

Abstract

Dihydroartemisinin/piperaquine (DHA-PPQ) 40/320 mg is approved for the treatment of Plasmodium falciparum uncomplicated malaria. Different recommendations are provided by WHO guidelines and drug data sheet about dosing in overweight patients. We report here a treatment failure likely caused by sub-optimal dosing of dihydroartemisinin-piperaquine in a case of uncomplicated P. falciparum malaria in a returning traveler from Burkina Faso.

To cite this article

Treatment failure due to the potential under-dosing of dihydroartemisinin-piperaquine in a patient with Plasmodium falciparum uncomplicated malaria

Infectious Diseases and Tropical Medicine 2019; 5: e525
DOI: 10.32113/idtm_20195_525

Publication History

Submission date: 01 Feb 2019

Revised on: 11 Mar 2019

Accepted on: 10 May 2019

Published online: 31 May 2019